MIRA Pharmaceuticals (MIRA) Competitors $1.50 +0.03 (+2.04%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$1.48 -0.02 (-1.33%) As of 08/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIRA vs. ZURA, SAVA, HLVX, COYA, CHRS, MGNX, CLYM, PLRX, ANIX, and ONCYShould you be buying MIRA Pharmaceuticals stock or one of its competitors? The main competitors of MIRA Pharmaceuticals include Zura Bio (ZURA), Cassava Sciences (SAVA), HilleVax (HLVX), Coya Therapeutics (COYA), Coherus Oncology (CHRS), MacroGenics (MGNX), Climb Bio (CLYM), Pliant Therapeutics (PLRX), Anixa Biosciences (ANIX), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry. MIRA Pharmaceuticals vs. Its Competitors Zura Bio Cassava Sciences HilleVax Coya Therapeutics Coherus Oncology MacroGenics Climb Bio Pliant Therapeutics Anixa Biosciences Oncolytics Biotech MIRA Pharmaceuticals (NASDAQ:MIRA) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk. Which has more volatility & risk, MIRA or ZURA? MIRA Pharmaceuticals has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Zura Bio has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500. Does the media prefer MIRA or ZURA? In the previous week, MIRA Pharmaceuticals and MIRA Pharmaceuticals both had 7 articles in the media. MIRA Pharmaceuticals' average media sentiment score of 0.89 beat Zura Bio's score of 0.58 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MIRA Pharmaceuticals 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zura Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in MIRA or ZURA? 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 14.2% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts recommend MIRA or ZURA? MIRA Pharmaceuticals presently has a consensus price target of $17.00, suggesting a potential upside of 1,033.33%. Zura Bio has a consensus price target of $14.17, suggesting a potential upside of 753.41%. Given MIRA Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe MIRA Pharmaceuticals is more favorable than Zura Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Zura Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has stronger earnings and valuation, MIRA or ZURA? MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMIRA PharmaceuticalsN/AN/A-$7.85M-$0.51-2.94Zura BioN/AN/A-$45.39M-$0.70-2.37 Is MIRA or ZURA more profitable? Zura Bio's return on equity of -47.44% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MIRA PharmaceuticalsN/A -329.63% -271.22% Zura Bio N/A -47.44%-38.81% SummaryMIRA Pharmaceuticals and Zura Bio tied by winning 6 of the 12 factors compared between the two stocks. Get MIRA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIRA vs. The Competition Export to ExcelMetricMIRA PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.03M$3.09B$5.66B$9.82BDividend YieldN/A2.23%3.79%4.07%P/E Ratio-3.0620.3830.5825.12Price / SalesN/A356.76462.42114.82Price / CashN/A42.3037.4059.05Price / Book11.548.659.096.18Net Income-$7.85M-$54.65M$3.25B$264.89M7 Day Performance8.70%6.58%7.32%4.18%1 Month Performance-19.79%7.54%5.41%1.99%1 Year Performance-22.28%13.73%30.66%24.22% MIRA Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MIRAMIRA Pharmaceuticals3.267 of 5 stars$1.50+2.0%$17.00+1,033.3%-20.2%$28.03MN/A-3.062Earnings ReportShort Interest ↓Gap UpZURAZura Bio3.678 of 5 stars$1.46-2.7%$14.33+881.7%-49.4%$102.56MN/A-2.093News CoverageEarnings ReportAnalyst ForecastSAVACassava Sciences2.0977 of 5 stars$2.29+8.0%$54.50+2,279.9%-91.8%$102.41MN/A-1.5330News CoverageEarnings ReportHLVXHilleVax1.7859 of 5 stars$2.07+1.5%$2.00-3.4%+14.9%$102.29MN/A-0.9620News CoverageHigh Trading VolumeCOYACoya Therapeutics1.6507 of 5 stars$6.34+4.1%$16.50+160.3%+22.8%$101.86M$3.69M-5.936News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionCHRSCoherus Oncology4.2277 of 5 stars$0.87-1.1%$4.68+439.6%-32.3%$101.77M$266.96M-0.77330MGNXMacroGenics4.3295 of 5 stars$1.64+3.8%$5.33+225.2%-51.5%$99.68M$152.43M-1.84430Trending NewsEarnings ReportAnalyst ForecastCLYMClimb Bio3.528 of 5 stars$1.70+17.2%$9.00+429.4%N/A$97.99MN/A-0.719News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumePLRXPliant Therapeutics3.8938 of 5 stars$1.70+7.6%$13.31+683.1%-87.5%$96.99M$1.58M-0.4790ANIXAnixa Biosciences2.5861 of 5 stars$3.26+8.3%$9.00+176.1%-6.9%$96.96M$210K-8.585ONCYOncolytics Biotech1.8623 of 5 stars$0.88-10.8%$4.33+390.7%+11.3%$96.43MN/A-3.0530Earnings ReportAnalyst Forecast Related Companies and Tools Related Companies Zura Bio Competitors Cassava Sciences Competitors HilleVax Competitors Coya Therapeutics Competitors Coherus Oncology Competitors MacroGenics Competitors Climb Bio Competitors Pliant Therapeutics Competitors Anixa Biosciences Competitors Oncolytics Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIRA) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MIRA Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MIRA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access